Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 13/20 | 0.41 |
| ▸ | IDH2 | P48735 | 9/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369842 | 0.88 | IDH1 (0.44) | IDH1IDH2 | |
| SCHEMBL2016378 | 0.84 | CCR1 (0.54) | KMT2AIDH1GRM5TGFBR1 | |
| SCHEMBL2015105 | 0.84 | LMNA (0.58) | KMT2AIDH1IDH2LMNAGRM5 | |
| SCHEMBL9370182 | 0.79 | MEN1 (0.52) | KMT2ALMNAMAPK1 | |
| SCHEMBL31127079 | 0.77 | CCR1 (0.58) | IDH1GRM5TGFBR1 | |
| SCHEMBL2241672 | 0.77 | CCR1 (0.58) | IDH1GRM5TGFBR1 | |
| SCHEMBL9370139 | 0.76 | KMO (0.47) | GRM5 | |
| SCHEMBL10370101 | 0.75 | NOS1 (0.39) | LMNATGFBR1FFAR1 | |
| SCHEMBL19690959 | 0.75 | KDM4E (0.58) | GRM5MAPK1FFAR1 | |
| SCHEMBL16369763 | 0.74 | IDH1 (0.47) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| EP-2066655-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008028935-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028935-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | KCNJ2, KCNN2, KCNN1 | KMT2A 1374/4885IDH1 1496/4885IDH2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.